Dotinurad

About Fortress Biotech

Fortress Biotech operates as a biopharmaceutical accelerator, leveraging a capital-efficient model to build a diversified portfolio of commercial and development-stage assets. Its strategy centers on acquiring overlooked assets and advancing them either internally or through subsidiary/partner companies, where it retains significant equity and royalty stakes. Recent achievements include the FDA approval of ZYCUBO® for Menkes disease and the $205 million monetization of the associated Priority Review Voucher, demonstrating its ability to create and capture substantial value. The company's value is multi-faceted, derived from product revenue, equity holdings, and structured financial returns from its network.

Therapeutic Areas